A report on Malaria, Chloroquine, Antimalarial medication and Plasmodium falciparum
Chloroquine is a medication primarily used to prevent and treat malaria in areas where malaria remains sensitive to its effects.
- ChloroquineAntimalarial medications or simply antimalarials are a type of antiparasitic chemical agent, often naturally derived, that can be used to treat or to prevent malaria, in the latter case, most often aiming at two susceptible target groups, young children and pregnant women.
- Antimalarial medicationPlasmodium falciparum is a unicellular protozoan parasite of humans, and the deadliest species of Plasmodium that causes malaria in humans.
- Plasmodium falciparumAs well, despite very positive outcomes from many modern treatments, serious side effects can impact some individuals taking standard doses (e.g., retinopathy with chloroquine, acute haemolytic anaemia with tafenoquine).
- Antimalarial medicationPractice in treating cases of malaria is most often based on the concept of combination therapy (e.g., using agents such as artemether and lumefantrine against chloroquine-resistant Plasmodium falciparum infection), since this offers advantages including reduced risk of treatment failure, reduced risk of developed resistance, as well as the possibility of reduced side-effects.
- Antimalarial medicationMost deaths are caused by P. falciparum, whereas P. vivax, P. ovale, and P. malariae generally cause a milder form of malaria.
- MalariaThe recommended treatment for malaria is a combination of antimalarial medications that includes artemisinin.
- MalariaIt is generally not used for Plasmodium falciparum as there is widespread resistance to it.
- ChloroquineIn areas where resistance is present, other antimalarials, such as mefloquine or atovaquone, may be used instead.
- ChloroquineResistance among the parasites has developed to several antimalarial medications; for example, chloroquine-resistant P. falciparum has spread to most malarial areas, and resistance to artemisinin has become a problem in some parts of Southeast Asia.
- MalariaIn the late 1930s, the Germans developed chloroquine, which went into use in the North African campaigns.
- Plasmodium falciparumAccording to WHO guidelines 2010, artemisinin-based combination therapies (ACTs) are the recommended first-line antimalarial treatments for uncomplicated malaria caused by P. falciparum.
- Plasmodium falciparum2 related topics with Alpha
Plasmodium vivax
1 linksProtozoal parasite and a human pathogen.
Protozoal parasite and a human pathogen.
This parasite is the most frequent and widely distributed cause of recurring malaria.
Although it is less virulent than Plasmodium falciparum, the deadliest of the five human malaria parasites, P. vivax malaria infections can lead to severe disease and death, often due to splenomegaly (a pathologically enlarged spleen).
Chloroquine remains the treatment of choice for vivax malaria, except in Indonesia's Irian Jaya (Western New Guinea) region and the geographically contiguous Papua New Guinea, where chloroquine resistance is common (up to 20% resistance).
Where an artemisinin-based combination therapy has been adopted as the first-line treatment for P. falciparum malaria, it may also be used for P. vivax malaria in combination with primaquine for radical cure.
Plasmodium
1 linksGenus of unicellular eukaryotes that are obligate parasites of vertebrates and insects.
Genus of unicellular eukaryotes that are obligate parasites of vertebrates and insects.
The ensuing destruction of host red blood cells can result in malaria.
Over the course of the 20th century, many other species were discovered in various hosts and classified, including five species that regularly infect humans: P. vivax, P. falciparum, P. malariae, P. ovale, and P. knowlesi.
A number of drugs have been developed to treat Plasmodium infection; however, the parasites have evolved resistance to each drug developed.
Resistance to quinine spurred the development of a broad array of antimalarial medications through the 20th century including chloroquine, proguanil, atovaquone, sulfadoxine/pyrimethamine, mefloquine, and artemisinin.